Latin America Cardiac Resynchronization Therapy Study (LatAmCRT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01238874|
Recruitment Status : Unknown
Verified March 2011 by Medtronic Latin America.
Recruitment status was: Enrolling by invitation
First Posted : November 11, 2010
Last Update Posted : March 29, 2011
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure.||Device: Cardiac Resynchronization Therapy||Phase 4|
The purpose of this study is to provide local evidence regarding Cardiac Resynchronization Therapy (CRT), in both pacing and defibrillation devices across Latin America. The primary objective will focus on changes in left ventricular heart size and function measurements in subjects receiving CRT therapy. The following additional parameters will also be collected:
- Data on referral patterns in Latin America;
- Data on device implant (including delivery system, device information, and lead information);
- Clinical data on subject outcomes and changes (improved, unchanged, or worsened) in heart failure status as assessed by heart failure (HF) hospitalizations, New York Heart Association (NYHA) class, mortality, and Quality of Life (QOL) measured by the Patient Global Assessment;
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Latin America Cardiac Resynchronization Therapy Study|
|Study Start Date :||February 2011|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2014|
No Intervention: No intervention
Mostly observational study with 1 patient global assessment.
Device: Cardiac Resynchronization Therapy
All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
- Measure heart size and function changes as assessed by Doppler echocardiogram (Echo). [ Time Frame: 6 Months ]Measure heart size and function changes as assessed by Doppler echocardiogram (Echo).
- referral patterns; Report on device implant; Analyze subject clinical status as it pertains to heart failure (HF) hospitalizations, changes in NYHA class, mortality and QOL (Patient Global Assessment); [ Time Frame: 6 Months ]referral patterns; Report on device implant; Analyze subject clinical status as it pertains to heart failure (HF) hospitalizations, changes in NYHA class, mortality and QOL (Patient Global Assessment);
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01238874
|Hospital Angeles Tijuana|
|Tijuana, Baja California, Mexico|
|Hospital Angeles Leon|
|Leon, Guanajuato, Mexico, OUS|